Dr. Grant R. Simons, MD
Cardiac Electrophysiology (Clinical Cardiac Electrophysiology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 567
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Cardiac Electrophysiology Physician primary
NJ license 25MA07277100
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Englewood Hospital and Medical Center Englewood, NJ
- Palisades Medical Center North Bergen, NJ
Medical groups
- Hackensack Meridian Health Medical Group - Specialty Care PC (1,922 clinicians)
- Medical Associates of Englewood PC (540 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 567
- Services billed
- 3,024
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 419 | 255 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 353 | 114 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 339 | 49 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 326 | 98 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 325 | 104 |
| Established patient office or other outpatient visit, 20-29 minutes | 290 | 194 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 115 | 35 |
| Programming of dual lead pacemaker system | 112 | 83 |
| New patient office or other outpatient visit, 45-59 minutes | 93 | 93 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 58 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Englewood, NJ | 71 |
| Amiodarone Hcl Other prescribers in Englewood, NJ | 57 |
| Metoprolol Succinate Other prescribers in Englewood, NJ | 55 |
| Multaq (dronedarone hcl) Other prescribers in Englewood, NJ | 39 |
| Xarelto (rivaroxaban) Other prescribers in Englewood, NJ | 20 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Englewood, NJ | 17 |
| Dofetilide | 13 |
| Amlodipine Besylate Other prescribers in Englewood, NJ | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 75 payments worth $43,616 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $32,835 |
|---|---|
| Abbott Laboratories | $9,636 |
| Medtronic, Inc. | $424 |
| Boston Scientific Corporation | $360 |
| Amgen Inc. | $117 |
| Cordis US Corp. | $98.08 |
| Abiomed | $35.14 |
| E.r. Squibb & Sons, L.l.c. | $31.09 |
| Consulting Fee | $32,835 |
|---|---|
| Speaking at a medical education program | $5,250 |
| Travel and Lodging | $3,703 |
| Food and Beverage | $1,828 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Mar 17, 2025 | Speaking at a medical education program AMPLATZER AMULET · Structural Heart | $5,250 |
| Novartis Pharmaceuticals Corporation Apr 30, 2025 | Consulting Fee KISQALI · Oncology | $3,990 |
| Novartis Pharmaceuticals Corporation Mar 31, 2025 | Consulting Fee KISQALI · Oncology | $2,940 |
| Novartis Pharmaceuticals Corporation Dec 31, 2025 | Consulting Fee KISQALI · Oncology | $2,835 |
| Novartis Pharmaceuticals Corporation Jul 31, 2025 | Consulting Fee KISQALI · Oncology | $2,520 |
| Novartis Pharmaceuticals Corporation Jun 30, 2025 | Consulting Fee KISQALI · Oncology | $2,450 |
| Novartis Pharmaceuticals Corporation Sep 30, 2025 | Consulting Fee KISQALI · Oncology | $2,380 |
| Novartis Pharmaceuticals Corporation May 31, 2025 | Consulting Fee KISQALI · Oncology | $2,170 |
| Novartis Pharmaceuticals Corporation Oct 31, 2025 | Consulting Fee KISQALI · Oncology | $2,065 |
| Novartis Pharmaceuticals Corporation Nov 30, 2025 | Consulting Fee KISQALI · Oncology | $2,030 |
All 34 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 31, 2025 | Consulting Fee KISQALI · Oncology | $2,835 |
| Novartis Pharmaceuticals Corporation Dec 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Nov 30, 2025 | Consulting Fee KISQALI · Oncology | $2,030 |
| Novartis Pharmaceuticals Corporation Nov 30, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Oct 31, 2025 | Consulting Fee KISQALI · Oncology | $2,065 |
| Novartis Pharmaceuticals Corporation Oct 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Abbott Laboratories Oct 22, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Philadelphia, PA · in-kind | $742 |
| Abbott Laboratories Oct 22, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Philadelphia, PA · in-kind | $597 |
| Abbott Laboratories Oct 22, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Philadelphia, PA · in-kind | $243 |
| Novartis Pharmaceuticals Corporation Sep 30, 2025 | Consulting Fee KISQALI · Oncology | $2,380 |
| Novartis Pharmaceuticals Corporation Sep 30, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Jul 31, 2025 | Consulting Fee KISQALI · Oncology | $2,520 |
| Novartis Pharmaceuticals Corporation Jul 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Jun 30, 2025 | Consulting Fee KISQALI · Oncology | $2,450 |
| Novartis Pharmaceuticals Corporation Jun 30, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation May 31, 2025 | Consulting Fee KISQALI · Oncology | $2,170 |
| Novartis Pharmaceuticals Corporation May 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Apr 30, 2025 | Consulting Fee KISQALI · Oncology | $3,990 |
| Novartis Pharmaceuticals Corporation Apr 30, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Mar 31, 2025 | Consulting Fee KISQALI · Oncology | $2,940 |
| Novartis Pharmaceuticals Corporation Mar 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Abbott Laboratories Mar 17, 2025 | Speaking at a medical education program AMPLATZER AMULET · Structural Heart | $5,250 |
| Abbott Laboratories Mar 17, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $63.71 |
| Abbott Laboratories Mar 17, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $53.07 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $688 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $512 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $338 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $232 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $225 |
| Abbott Laboratories Mar 6, 2025 | Travel and Lodging AMPLATZER AMULET · Structural Heart · travel to Arlington, VA · in-kind | $9.02 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Consulting Fee KISQALI · Oncology | $2,030 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Consulting Fee KISQALI · Oncology | $500 |
| Novartis Pharmaceuticals Corporation Jan 31, 2025 | Consulting Fee KISQALI · Oncology | $1,925 |
| Novartis Pharmaceuticals Corporation Jan 31, 2025 | Consulting Fee KISQALI · Oncology | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,489 in research payments for these studies, mostly to the institutions running them.
- CHAMPION-AF Clinical Trial
Boston Scientific Corporation · Active, not recruiting · NCT04394546
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.